Moors & Cabot’s Recursion Pharmaceuticals RXRX Stock Holding History

Moors & Cabot’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38.7K	Sell	12,600 -15,150	-55%	-$58.5K	﹤0.01%	918
2025 Q4	$113K	Sell	27,750 -896	-3%	-$4.44K	﹤0.01%	886
2025 Q3	$140K	Sell	28,646 -15,904	-36%	-$83.5K	0.01%	866
2025 Q2	$225K	Buy	44,550 +680	+2%	+$3.34K	0.01%	760
2025 Q1	$232K	Buy	+43,870	New	+$320K	0.01%	729
2024 Q2	–	Sell	-13,500	Closed	-$135K	–	930
2024 Q1	$135K	Buy	+13,500	New	+$150K	0.01%	847

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Moors & Cabot's RXRX Position: Q1 2026 in Review

Moors & Cabot reduced its Recursion Pharmaceuticals (RXRX) stake by 55% in Q1 2026, selling an estimated $58.5K and leaving 12,600 shares worth $38.7K. The position accounts for ﹤0.01% of the portfolio, ranked #918.

Moors & Cabot first reported a position in RXRX in Q1 2024 and has held it in 6 quarters since. The position peaked at $232K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Moors & Cabot held 12,600 shares of Recursion Pharmaceuticals worth $38.7K as of Q1 2026.
Moors & Cabot sold 15,150 Recursion Pharmaceuticals shares in Q1 2026, an estimated $58.5K.
Recursion Pharmaceuticals made up ﹤0.01% of Moors & Cabot's portfolio in Q1 2026, its #918 holding.
Moors & Cabot first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
Moors & Cabot's Recursion Pharmaceuticals position peaked at $232K in Q1 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.